Resveratrol-Leucine Metabolite Synergy in Pre-diabetes
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study will evaluate the effects of resveratrol/leucine and resveratrol/HMB for their ability to control glucose levels in persons without diabetes but with impaired fasting glucose. Secondary assessments will examine the effect of these nutritional supplements versus placebo on inflammation, fasting lipids, HbA1C, and fructosamine, longer term metabolic markers of risk in diabetes.
| Condition | Intervention |
|---|---|
|
Impaired Glucose Tolerance |
Dietary Supplement: Resveratrol Dietary Supplement: resveratrol /HMB Other: Placebo treatment |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Resveratrol-Leucine Metabolite Synergy in Pre-diabetes |
- Glucose Control [ Time Frame: 28 days ] [ Designated as safety issue: No ]We will evaluate the effects of resveratrol/leucine and resveratrol/HMB for their ability to control glucose levels in persons without diabetes but with impaired fasting glucose
- Metabolic Markers [ Time Frame: 28 days ] [ Designated as safety issue: No ]Secondary assessments will examine the effect of these nutritional supplements versus placebo on inflammation, fasting lipids, HbA1C, and fructosamine, longer term metabolic markers of risk in diabetes
| Estimated Enrollment: | 36 |
| Study Start Date: | February 2012 |
| Estimated Study Completion Date: | April 2013 |
| Estimated Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Dietary Supplement/insulin sensitivity
The first study supplement contains resveratrol that may improve insulin sensitivity and Leucine.Resveratrol 50mg with leucine 1.11 g. - one tablet taken twice a day by mouth
|
Dietary Supplement: Resveratrol
A blend of low dose resveratrol and either leucine or HMB will be useful nutraceutical strategies for the control of elevated blood glucose in non-diabetic individuals with elevated fasting glucose. The proposed project is designed to evaluate this hypothesis by comparing the effects of resveratrol (50 mg)/leucine (1.11 g) administered twice daily (bid).
|
|
Placebo Comparator: Sugar Pill
Neutral treatment Placebo - one tablet taken twice a day by mouth
|
Other: Placebo treatment
Placebo - one tablet taken twice a day by mouth
|
|
Active Comparator: Dietary Supplement 2
2nd study supplement contains resveratrol and HMB which may stimulate protein building.
|
Dietary Supplement: resveratrol /HMB
resveratrol (50 mg)/HMB (500 mg) twice daily (bid) with placebo on fasting blood glucose, glucose tolerance, insulin, C-peptide, glucagon, fructosamine and F2-isoprostanes in non-diabetic subjects with elevated fasting blood glucose.
|
Detailed Description:
This will be a 28-day randomized controlled trial of the effects of a nutraceutical preparation on glycemic control in non-diabetic individuals with impaired glucose tolerance (IGT). IGT will be defined by American Diabetes Association criteria, as outlined in the list of inclusion and exclusion criteria (copy attached). There will be two active treatment arms and a placebo arm (3 arms total, n=12 completed subjects per arm). Following screening for inclusion/exclusion criteria and obtaining informed consent, subjects will be enrolled in the study and provided instructions to maintain their usual dietary pattern and physical activity level. If recent physical examination and medical history are not available; H&P will be conducted and recorded for each enrolled subject. Subjects will be instructed to follow a 12-hour fast starting on day -1, and on the morning of day 0 fasting blood is drawn for analyses indicated below and the supplements are distributed. Supplements are distributed using a blinding protocol and a variable, known pill allotment in order to assess compliance via standard pill counts. Pill bottles and all unused supplements are returned at seven day intervals, with new supplies being distributed at that time. Fasting blood samples are obtained on days 0, 7, 14 and 28. Samples from each day are analyzed for glucose and insulin. Samples from days 0, 14 and 28 are also analyzed for fructosamine, C-peptide, glucagon and F2-isoprostanes. A75 g oral glucose tolerance test administered on days 0 and 28.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Impaired fasting glucose as defined by American Diabetes Association criteria: fasting plasma glucose level from 5.6 mmol/L (100 mg/dL) to 6.9 mmol/L (125 mg/dL)
- Body mass index (BMI) 25-34.9
- Age 18 and above• Weight stable: no more than 1 kg weight gain or loss during past 12 weeks
Exclusion Criteria:
- Fasting glucose >126 or <99 mg/dL
- BMI < 25 or >35
- Current/previous diagnosis of diabetes
- History of eating disorder or presence of active gastrointestinal disorders such as malabsorption syndromes
- Pregnancy or lactation Anemia, defined as hemoglobin level less than 10g/dl.
- Use of obesity pharmacotherapeutic agents within the last 6 months
- Use of over-the-counter anti-obesity agents (e.g. those containing phenylpropylamine , ephedrine and/or caffeine) within the last 3 months
- Chronic use of anti-inflammatory agents within the last four weeks
- Use of antioxidant supplements within the last four weeks including selenium, vitamin E, vitamin C and/or carotenoids
- Use of supplements containing any of the study compounds within the past four weeks
- Recent (current or past 12 weeks) use of any psychotropic medication
- Recent (past four weeks) initiation of or change in an exercise program
- Recent (past twelve weeks) initiation of hormone replacement therapy or change in HRT regimen
- Recent (past twelve weeks) initiation of hormonal birth control or change in hormonal birth control regimen
- Recent (past 12-weeks) history of tobacco use
- Any Condition that the P.I. considers adverse to the participant
Contacts and Locations| Contact: Wanda Snead, Dr.HSc | 615-936-1625 | wanda.snead@vanderbilt.edu |
| Contact: Libby Stone, RN | 615-936-1149 | libby.stone@vanderbilt.edu |
| United States, Tennessee | |
| Facility: Vanderbilt University | Recruiting |
| Nashville, Tennessee, United States, 37232 | |
| Contact: Wanda L. Snead, Dr.HSc 615-936-1625 wanda.snead@vanderbilt.edu | |
| Contact: Libby Stone, RN 615-936-1145 Libby.stone@vanderbilt.edu | |
| Principal Investigator: Kevin Niswender, MD,PhD | |
| Principal Investigator: | Kevin D Niswender, MD,PHD | Vanderbilt University School of Medicine |
More Information
Publications:
| Responsible Party: | Wanda Snead, Study Sub-Investigator/Coordinator, Vanderbilt University |
| ClinicalTrials.gov Identifier: | NCT01593605 History of Changes |
| Other Study ID Numbers: | KNIS-NCI |
| Study First Received: | May 2, 2012 |
| Last Updated: | June 21, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Vanderbilt University:
|
Impaired glucose tolerance, pre-diabetes,glycemic control, supplements |
Additional relevant MeSH terms:
|
Glucose Intolerance Prediabetic State Hyperglycemia Glucose Metabolism Disorders Metabolic Diseases Diabetes Mellitus Endocrine System Diseases Resveratrol Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions |
Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Antineoplastic Agents, Phytogenic Antineoplastic Agents Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Enzyme Inhibitors Platelet Aggregation Inhibitors Hematologic Agents Antimutagenic Agents Anticarcinogenic Agents Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 22, 2013